- Get in Touch with Us
Last Updated: Apr 26, 2025 | Study Period: 2024-2030
Coronary artery disease (CAD) is the most common kind of heart disease, affecting over Americans.
The most common cause of CAD is atherosclerosis, which occurs when a waxy material accumulates inside the arteries that carry blood to heart. As the plaque accumulates, the artery narrows, making blood flow to the heart more difficult.
As the blockage worsens, blood flow to the heart decreases, and a condition known as angina develops. A constricted or clogged artery might eventually lead to a heart attack.
A variety of medications can be used to treat the angina discomfort associated with CAD. However, because drugs cannot remove clogged arteries, a severely constricted coronary artery may require surgery.
Angioplasties, which open narrowed arteries, are performed by interventional cardiologists. They utilize a catheter, which is a long, thin tube with a little balloon on the tip.
They inflate the balloon at the site of the arterial blockage in order to flatten or compress the plague against the artery wall. Percutaneous transluminal coronary angioplasty (PTCA) is another name for angioplasty.
Although this item focuses on the coronary arteries in the heart, balloon angioplasty may be used to widen restricted veins in many other places of the body.
Carotid angioplasty, for example, can be used to widen constricted carotid arteries, which are the arteries that feed blood to the brain.
A stroke most commonly develops when the carotid arteries get clogged, preventing adequate oxygen from reaching the brain.
Angioplasties, which open narrowed arteries, are performed by interventional cardiologists. They utilize a catheter, which is a long, thin tube with a little balloon on the tip.
They inflate the balloon at the site of the arterial blockage in order to flatten or compress the plague against the artery wall. Percutaneous transluminal coronary angioplasty (PTCA) is another name for angioplasty.
Although this item focuses on the coronary arteries in the heart, balloon angioplasty may be used to widen restricted veins in many other places of the body.
Carotid angioplasty, for example, can be used to widen constricted carotid arteries, which are the arteries that feed blood to the brain. A stroke is most commonly caused when the carotid arteries get clogged and the brain does not receive enough oxygen.
A stent is a tiny, metal mesh-like device. When a stent is inserted into a coronary artery, it works as a scaffold or support, keeping the conduit open.
The stent improves blood flow to the heart muscle and reduces angina symptoms by keeping the channel open. Stent treatments are frequently performed in conjunction with balloon angioplasty. In fact, around 80% of patients who have balloon angioplasty will also have a stent put.
Stents, like balloon angioplasty, are now used in many other regions of the body than the heart. Stents can also be implanted in the neck's carotid arteries, the aorta, and the legs peripheral arteries. Angioplasty can also be used for
Doctors are always looking for novel techniques to keep arteries from shutting again following an angioplasty or stent surgery.
Doctors have employed new types of stents in recent years. Some of them are coated with medications that prevent the artery from shutting again.
These coated stents gradually release their medication into the surrounding tissue, delaying or preventing restenosis. Coated stents have shown promise in terms of increasing the procedure's long-term success.
Tiny stents and custom-designed stents are also being developed by researchers to fit into tiny arteries.
They are also developing stents for veins with multiple blockages, such as those with side branches. To prevent blood clots from developing within the stent, other stents are being coated with blood-thinning medications.
Researchers have lately begun designing non-metal stents that will dissolve into the artery over time. These stents open the artery similarly to metal stents, but they lessen the danger of restenosis since they do not remain in the artery.
The Global Balloon Angioplasty Catheters Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Medtronic plc, a worldwide leader in medical technology, today announced the availability of the Prevail drug-coated balloon (DCB) catheter in Europe following CE (Conformité Européene) certification.
The Prevail DCB, the most recent coronary DCB on the market, is used during percutaneous coronary intervention (PCI) operations to treat restricted or blocked coronary arteries in patients with coronary artery disease (CAD).
The balloon is inflated within the artery during the catheter-based operation, and the medication is administered to the arterial tissue, where it is absorbed.
The Prevail DCB employs paclitaxel, a medication with quick absorption, to treat de novo lesions, small vascular disease, and in-stent restenosis (ISR).
DCB angioplasty does not need a permanent implant and is frequently used in situations when the placement of a permanent implant is not possible.
As physicians treat more patients with complicated lesions, it is vital to have a drug-coated balloon that is highly deliverable across a wide range of vasculatures and uses a medication that absorbs fast into the artery.
The Prevail DCB is a fantastic alternative for interventional cardiologists who use DCB technology to treat their patients due to its high deliverability and a strong safety profile supported by clinical evidence.
The PREVAIL DCB expands on the previous generation IN.PACT Falcon DCB clinical program's exceptional safety and efficacy, which was reinforced by the PREVAIL Study presented at the PCR e-Course conference.
The Prevail DCB performed exceptionally well in the PREVAIL Study in patients with complicated lesions, including those with tiny arteries and those treated with chemotherapy.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.